Gumokimab vs HB0017

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A · full Psoriasis pipeline

Gumokimab

Marketed by Akeso

Phase 3 in Psoriasismonoclonal antibody
Partial signal

NCT06066125 · Phase 3 · completed

The trial was properly randomized, quadruple-blinded, and placebo-controlled with over 350 participants and used hard, regulator-accepted clinical endpoints (PASI75 and sPGA 0/1). However, the only externally available result reports the gumokimab arm's response rate without the placebo arm's rate or any statistical test, so it isn't possible to confirm the pre-specified comparison was statistically significant, which keeps this well-designed trial at a moderate grade rather than strong.

Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.

Reported efficacy

The percentage of subjects who achieved at least 75% reduction in psoriasis area and severity index(PASI) score from baseline (PASI 75) and the percentage of subjects who achieved static physician global assessment(sPGA) 0/1 at week 12.: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7% (unclear)

Result source: NCT06066125

HB0017

Developed by Huabo Biopharm Co.

Phase 3 in Psoriasismonoclonal antibody
Partial signal

NCT06477237 · Phase 3 · completed

This is a randomized, quadruple-blind, placebo-controlled Phase 3 trial using validated psoriasis response measures as its primary endpoints, but no results are yet posted to the registry, so the outcome is unknown.

Next expected readout: December 2026 · NCT07920861 (registry estimate)

Reported efficacy

PASI 90 response (Week 12); sPGA 0/1 response (Week 12): Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens. (unclear)

Result source: NCT05531682

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGumokimabHB0017
PASI 75—Not posted · NCT06066125—Not posted · NCT06477237
PASI 90—Not posted · NCT06066125—Not posted · NCT06477237
PASI 100—Not posted · NCT06066125—Not posted · NCT06477237
sPGA 0/1—Not posted · NCT06066125—Not posted · NCT06477237
DLQI, change—Not posted · NCT06066125—Not posted · NCT06477237

PASI 75

Gumokimab
—Not posted · NCT06066125
HB0017
—Not posted · NCT06477237

PASI 90

Gumokimab
—Not posted · NCT06066125
HB0017
—Not posted · NCT06477237

PASI 100

Gumokimab
—Not posted · NCT06066125
HB0017
—Not posted · NCT06477237

sPGA 0/1

Gumokimab
—Not posted · NCT06066125
HB0017
—Not posted · NCT06477237

DLQI, change

Gumokimab
—Not posted · NCT06066125
HB0017
—Not posted · NCT06477237
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Gumokimab
PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7% NCT06066125 · Phase 3 · design grade: moderate · publication or press release
HB0017
Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens. NCT05531682 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gumokimab's landscape · HB0017's landscape